Integra LifeSciences (NASDAQ:IART - Get Free Report) announced its quarterly earnings results on Monday. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02, Briefing.com reports. The business had revenue of $380.80 million for the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business's quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.76 EPS.
Integra LifeSciences Trading Up 3.3 %
Integra LifeSciences stock traded up $0.79 during midday trading on Tuesday, reaching $24.91. The stock had a trading volume of 1,746,243 shares, compared to its average volume of 1,101,824. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $45.42. The company has a fifty day moving average of $18.68 and a 200 day moving average of $24.41. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of 83.97, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17.
Analysts Set New Price Targets
IART has been the subject of several research analyst reports. BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Bank of America cut their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. Morgan Stanley lifted their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an "underweight" rating in a research note on Monday, July 15th. Finally, Citigroup upped their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research report on Tuesday. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $27.25.
Check Out Our Latest Analysis on IART
About Integra LifeSciences
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Recommended Stories
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
